Overview

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Status:
Terminated
Trial end date:
2020-02-12
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II clinical trial to evaluate the feasibility of administering talimogene laherparepvec into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Amgen
CareFusion
Treatments:
Antibodies, Monoclonal
Nivolumab
Talimogene laherparepvec